SHARON PLON, PHD
Medical Practice at Fannin St, Houston, TX

5674996, Oct 7, 1997

Feb 18, 1994

8/198446

Leland H. Hartwell - Seattle WA
Ted A. Weinert - Tucson AZ
Sharon E. Plon - Houston TX
Mark T. Groudine - Seattle WA

University of Washington - Seattle WA
Arizona Board of Regents on behalf of the University of Arizona - Tucson AZ
Fred Hutchinson Cancer Research Center - Seattle WA

C07H 2104

536 2431

Human checkpoint huCDC34, huRAD9. sub. compA, and huRAD9. sub. compB cDNAs shown in SEQ ID Nos:7-9. A method for isolating a human checkpoint cDNA that is capable of restoring growth at a restrictive temperature in a yeast test cell, wherein the yeast test cell comprises a genome having a first gene that forms a DNA strand break at a restrictive temperature and a second gene that fails to induce a cell cycle arrest in response to the DNA strand break, whereby the growth of the yeast test cell is inhibited at the restrictive temperature, the method comprising the steps of: obtaining a human cDNA library comprising a plurality of human cDNA clones; inserting the human cDNA clones individually into plasmid vectors comprising a selectable marker gene; transforming a culture of the yeast test cells with the plasmid vectors from the preceding step; selecting for yeast test cells transformed with the selectable marker gene; growing the selected transformants at the restrictive temperature and isolating a candidate transformant capable of growing at the restrictive temperature; and identifying the human cDNA carried by the candidate transformant as a human checkpoint cDNA by sequencing the human cDNA carried by the candidate transformant and determining that the human cDNA is less than 50% homologous with both the first gene and the second gene. Also yeast checkpoint RAD17, RAD24, MEC1, MEC2, and MEC3 cDNAs shown in SEQ ID Nos:10-19.

5866338, Feb 2, 1999

Jun 6, 1997

8/870693

Leland H. Hartwell - Seattle WA
Ted A. Weinert - Tucson AR
Sharon E. Plon - Houston TX
Mark T. Groudine - Seattle WA

University of Washington - Seattle WA
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Fred Hutchinson Cancer Research Center - Seattle WA

C12Q 168

435 6

Human checkpoint huCDC34, huRAD9. sub. compA, and huRAD9. sub. compB cDNAs shown in FIGS. 1, 2, and 3. A method for isolating a human checkpoint cDNA that is capable of restoring growth at a restrictive temperature in a yeast test cell, wherein the yeast test cell comprises a genome having a first gene that forms a DNA strand break at a restrictive temperature and a second gene that fails to induce a cell cycle arrest in response to the DNA strand break, whereby the growth of the yeast test cell is inhibited at the restrictive temperature, the method comprising the steps of: obtaining a human cDNA library comprising a plurality of human cDNA clones; inserting the human cDNA clones individually into plasmid vectors comprising a selectable marker gene; transforming a culture of the yeast test cells with the plasmid vectors from the preceding step; selecting for yeast test cells transformed with the selectable marker gene; growing the selected transformants at the restrictive temperature and isolating a candidate transformant capable of growing at the restrictive temperature; and identifying the human cDNA carried by the candidate transformant as a human checkpoint cDNA by sequencing the human cDNA carried by the candidate transformant and determining that the human cDNA is less than 50% homologous with both the first gene and the second gene. Also yeast checkpoint RAD17, RAD24, MEC1, MEC2, and MEC3 cDNAs shown in FIGS. 4-8.

2003011, Jun 26, 2003

Feb 25, 2002

10/084817

Susan Stuart - Montara CA, US
Jed Nuchtern - Houston TX, US
Sharon Plon - Houston TX, US
Jason Shohet - Pearland TX, US

C12Q001/68, C07H021/04, C12P019/34, C12N009/00, C12P021/02, C12N005/08

435/006000, 435/069100, 435/091200, 435/183000, 435/320100, 435/368000, 536/023200

The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed by MYCN activation and which may be used in their entirety or in part to diagnose, to stage, to treat, or to monitor the treatment of a subject with neuroblastoma.